The Democratic Republic of Congo (DRC) and Uganda are facing a new wave of Bundibugyo Ebola outbreak. The international scientific community is mobilizing to fill a vaccination gap that has persisted since the emergence of this viral strain.

Since the beginning of 2026, health authorities have recorded several confirmed cases of Ebola in locations such as Bunia in the DRC and Kasese in Uganda. These regions, already weakened by armed conflicts, are now confronted with the threat of a deadly disease, further complicating the health response.

Cross-border vaccination initiatives have been considered. In 2019, a report indicated that nearly 60,000 people, including traders and cross-border workers, were to be vaccinated to prevent any spread of the virus between the two countries. This strategy remains crucial as economic exchanges continue despite the health crisis.

Ugandan researchers have also launched a clinical trial for an experimental Ebola vaccine. This project aims to assess the immune response and safety of the vaccine on about 800 participants, including healthcare personnel. The results of this trial could provide vital information for the fight against the current outbreak.

However, some voices are raised against the use of new vaccines without prior testing. Congolese lawmakers have expressed concerns that populations could become "guinea pigs" for untested vaccines. These concerns highlight the importance of clear and transparent communication regarding clinical trials and vaccination campaigns.

Health authorities in both countries continue to work hand in hand to contain this outbreak. Regular meetings are held between Ugandan and Congolese health officials to establish joint strategies in response to this growing health crisis.